Deutsche Bank Ag\ 9 Meters Biopharma, Inc. Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.26 - $0.64 $35,052 - $86,282	-134,817 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.52 - $1.0 $7,588 - $14,594	-14,594 Reduced 9.77%	134,817 $81,000
Q4 2021 Feb 11, 2022	SELL	$0.85 - $1.33 $789,821 - $1.24 Million	-929,202 Reduced 86.15%	149,411 $146,000
Q3 2021 Nov 04, 2021	SELL	$1.03 - $1.41 $2.15 Million - $2.94 Million	-2,087,259 Reduced 65.93%	1,078,613 $1.4 Million
Q2 2021 Aug 11, 2021	BUY	$1.04 - $1.5 $3.16 Million - $4.56 Million	3,037,560 Added 2367.32%	3,165,872 $3.48 Million
Q1 2021 May 13, 2021	BUY	$0.84 - $2.16 $76,752 - $197,363	91,372 Added 247.35%	128,312 $150,000
Q3 2020 Nov 12, 2020	BUY	$0.48 - $0.84 $17,731 - $31,029	36,940 New	36,940 $30,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.